Pharmacotherapy for obesity: novel agents and paradigms
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Public health initiatives focused on obesity prevention and lifestyle intervention programmes for patients with obesity have struggled to contain the obesity epidemic to date. In recent years, antiobesity drug therapies have had a limited role in clinical treatment algorithms for patients with obesity. Indeed, a number of high-profile antiobesity drug suspensions have markedly impacted upon the landscape of obesity pharmacotherapy. In this review, we discuss the advent of an increasing array of pharmacotherapeutic agents, which are effective both in inducing weight loss and in maintaining weight loss achieved by lifestyle measures. The development of these drugs as antiobesity agents has followed varying paths, ranging from lorcaserin, a selective serotonin agent, exploiting the beneficial central actions of fenfluramine but without the associated systemic side effects, to liraglutide, a gut hormone already used as a glucose-lowering drug but with appetite-suppressant properties, or the novel drug combination of phentermine/topiramate, two ‘old’ drugs used in lower doses than with previous therapeutic uses, resulting in an additive effect on weight loss and fewer side effects. We summarize the key findings from recent randomized controlled trials of these three drugs. Although these agents lead to clinically important weight loss when used as monotherapy, the use of antiobesity drugs as adjunctive therapy post intensive lifestyle intervention could prove to be the most successful strategy. Moreover, a progressive approach to obesity pharmacotherapy perhaps offers the best opportunity to finally address the obesity crisis on a mass scale.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
the GIANT Consortium (2009) · Nature Genetics · doi:10.1038/ng.287 · Cited by 1,720
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Long-term weight-loss maintenance: a meta-analysis of US studies
Anderson, J. W., Konz, E. C., Frederich, R. C., & Wood, C. L. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/74.5.579 · Cited by 1,351 · cited 1×
“However in the long term, most will regain much of their lost weight [Anderson et al. 2001].”
BackgroundAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“pdf accessed 21 August 2013) and the USA as a fallout from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial [James et al. 2010] that showed a higher frequency of nonfatal myocardial infarction and stroke in subjects on sibutramine treatment compared with placebo.”
Self-citationGenomics, type 2 diabetes, and obesity
McCarthy, M. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906948 · Cited by 938 · cited 1×
“2013], translation of these discoveries into preventive and therapeutic measures of direct clinical benefit has proven to be extremely challenging [McCarthy, 2010], and ‘personalized’ obesity therapy currently remains beyond tangible reach [El-Sayed Moustafa and Froguel, 2013].”
BackgroundMulticenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 1×
“In the 2-year Behavioural modification and Lorcaserin for Overweight and Obesity Management (BLOOM) trial [Smith et al. 2010], 3182 subjects with a BMI of 30–45 kg/m2 or 27–45 kg/m2 and at least one weightrelated comorbidity were randomized to receive placebo twice daily or lorcaserin 10 mg twice daily, with completer…”
Methodon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Self-citationAllison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Hutter, M. M., Schirmer, B. D., Jones, D. B., Ko, C. Y., Cohen, M. E., Merkow, R. P., & Nguyen, N. T. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31822c9dac · Cited by 673
Berndt, S. I., Gustafsson, S., Mägi, R., Ganna, A., Wheeler, E., Feitosa, M. F., Justice, A. E., Monda, K. L., Croteau-Chonka, D. C., Day, F. R., et al. (2013) · Nature Genetics · doi:10.1038/ng.2606 · Cited by 646 · cited 1×
“While substantial advances have been made in the study of genetic factors underlying obesity susceptibility [Berndt et al. 2013; Magi et al. 2013], including the identification of increasing numbers of genetic variants associated with the risk of obesity [Wheeler et al.”
BackgroundWeight Recidivism Post-Bariatric Surgery: A Systematic Review
Karmali, S., Brar, B., Shi, X., Sharma, A. M., de Gara, C., & Birch, D. W. (2013) · Obesity Surgery · doi:10.1007/s11695-013-1070-4 · Cited by 574
Foster, G. D., Wadden, T. A., Vogt, R. A., & Brewer, G. (1997) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.65.1.79 · Cited by 447
Loveman, E., Frampton, G., Shepherd, J., Picot, J., Cooper, K., Bryant, J., Welch, K., & Clegg, A. (2011) · Health Technology Assessment · doi:10.3310/hta15020 · Cited by 296 · cited 1×
“Lifestyle intervention programmes which may include dietetic, exercise or psychological aspects, are effective in reducing weight in the short to medium term [Finer, 2001; Loveman et al. 2011], as are more intensive meal replacements or very low energy diets for patients with severe obesity (BMI ≥ 35 kg/m2) [Saris, 20…”
BackgroundA Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296 · cited 1×
“Concerns on an association between GLP-1 agonists and pancreatitis and pancreatic cancer have been raised [Butler et al. 2013; Cohen, 2013].”
Backgroundon behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210
Self-citationO'Rahilly, S., & Farooqi, I. S. (2008) · Diabetes · doi:10.2337/db08-0210 · Cited by 205
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · cited 1×
“Furthermore, mechanistic studies in patients with T2D suggest that the weight loss may involve combined effects on energy intake and energy expenditure [Horowitz et al. 2012].”
BackgroundDunkley, A. J., Charles, K., Gray, L. J., Camosso‐Stefinovic, J., Davies, M. J., & Khunti, K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01571.x · Cited by 151
Topiramate: Long‐Term Maintenance of Weight Loss Induced by a Low‐Calorie Diet in Obese Subjects
Astrup, A., Caterson, I., Zelissen, P., Guy‐Grand, B., Carruba, M., Levy, B., Sun, X., Fitchet, M., & OBES‐004 Study Group (2004) · Obesity Research · doi:10.1038/oby.2004.206 · Cited by 143
Lean, M., Brosnahan, N., McLoone, P., McCombie, L., Higgs, A. B., Ross, H., Mackenzie, M., Grieve, E., Finer, N., Reckless, J., et al. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x663073 · Cited by 87
Self-citation
Cited by
Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice
Alexopoulos, S. J., Chen, S.-Y., Brandon, A. E., Salamoun, J. M., Byrne, F. L., Garcia, C. J., Beretta, M., Olzomer, E. M., Shah, D. P., Philp, A. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16298-2 · Cited by 137
Anti-ghrelin antibodies in appetite suppression: Recent advances in obesity pharmacotherapy
Rotkvic, V., & Altabas, V. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s60398 · Cited by 32
“This action therefore provides other means for decreasing energy intake.(33,34) Since stabile long-term and profound weight reduction as a desired treatment goal is difficult to achieve with currently available antiobesity drugs alone, diet and proper physical activity are still of greatest importance in obesity manag…”
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“In addition, the trials have to show that the rate at which participants lose 5% of their baseline weight is at least twice as high in the treatment group versus the placebo group.(42) Clinical trials of drugs conducted before 1975 were generally short-term because it was widely believed that treatment would “cure obe…”
Background
Metadata
- Authors
- Manning, S., Pucci, A., & Finer, N.
- Venue
- Therapeutic Advances in Chronic Disease
- Publisher
- SAGE Publications
- Published
- 2014-02-19
- Volume
- 5
- Issue
- 3
- Pages
- 135-148
- ISSN
- 2040-6223 (ISSN-L)
- 2040-6231
- OpenAlex
- W2135201954
- Cited by
- 92
- References
- 29
- FWCI
- 13.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.